<DOC>
	<DOCNO>NCT02341209</DOCNO>
	<brief_summary>This study look efficacy Doxycycline treatment Cutaneous T-cell Lymphomas .</brief_summary>
	<brief_title>Doxycycline Treatment Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>The aim study evaluate efficacy doxycycline relapse Cutaneous T-cell Lymphomas ( CTCL ) . The primary objective determine overall response rate doxycycline monotherapy patient relapse CTCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Voluntarily sign date Institutional Review Board approve inform consent form accordance regulatory institutional guideline . Written informed consent must obtain prior perform studyrelated procedure . Be 18 year age old time enrollment . Measurable disease least one target lesion skin able assessed radiographic examination FDGPET fluorodeoxyglucose possitron emission tomography ( FDGPET ) scan computarized tomography ( CT ) scan , peripheral blood show involvement lymphoma . The subject resolution clinically significant toxic effect prior cancer therapy Grade ≤1 National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCICTCAE , v.4.0 ) exclude specification . Adequate organ function : Absolute Neutrophil Count ( ANC ) &gt; 500 cells/mL platelet count &gt; 50,000 cells/mL unless felt secondary lymphoma count permissible . Adequate renal function determine creatinine &lt; 1.5x upper limit normal ( ULN ) estimate creatinine clearance ≥ 60ml/min Adequate hepatic function determine total bilirubin &lt; 1.5x ULN ( unless know Gilbert syndrome ) , Alanine transaminase ( ALT ) Aspartate transaminase ( AST ) &lt; 2.5x ULN Confirmed diagnosis CTCL . Karnofsky Performance Status ≥ 60 % Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day receive study medication monthly receive doxycycline WOCBP must agree use effective contraception , define , oral contraceptive , double barrier method ( condom plus spermicide diaphragm plus spermicide ) practice true abstinence sexual intercourse ( periodic abstinence , e.g. , calendar ovulation , symptothermal , postovulation method withdrawal acceptable method contraception ) study 3 month last dose . WOCBP include female experience menarche undergone successful surgical sterilization postmenopausal ( define amenorrhea ≥ 12 consecutive month without alternative medical cause ) . Male subject female partner child bear potential must willing use appropriate method contraception define , oral contraceptive , double barrier method ( condom plus spermicide diaphragm plus spermicide ) practice true abstinence sexual intercourse ( periodic abstinence , e.g. , calendar , ovulation , symptothermal , postovulation method withdrawal acceptable method contraception ) study 3 month last dose . Known sensitivity allergy tetracycline Lack measurable disease Karnofsky Performance Status &lt; 60 % Inadequate organ function measure fulfil criterion Subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Sezary Syndrome ( SS )</keyword>
	<keyword>Mycosis Fungoides ( MF )</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>MF</keyword>
	<keyword>SS</keyword>
</DOC>